Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5716004 | 1.00 | ALDH1A1 (0.44) | ALDH1A1TDP1TSHROPRM1CYP3A4 | |
| SCHEMBL14679783 | 0.87 | ALDH1A1 (0.44) | ALDH1A1TDP1 | |
| SCHEMBL13890707 | 0.86 | ALDH1A1 (0.64) | ALDH1A1TDP1TSHROPRM1CYP3A4 | |
| SCHEMBL9343058 | 0.85 | ALDH1A1 (0.54) | ALDH1A1TDP1 | |
| SCHEMBL7602462 | 0.82 | TSHR (0.38) | ALDH1A1TDP1TSHROPRM1CYP3A4 | |
| SCHEMBL20244665 | 0.81 | ALDH1A1 (0.44) | ALDH1A1TDP1TSHRCA12CA1 | |
| SCHEMBL25120947 | 0.79 | TSHR (0.46) | ALDH1A1TDP1TSHROPRM1 | |
| SCHEMBL17928911 | 0.79 | — | — | |
| SCHEMBL18085391 | 0.79 | — | — | |
| SCHEMBL104640 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017201347-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |